Search results
Showing 451 to 500 of 601 results for women's health
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
surgery and full Consultant led obstetric and paediatric hospital services for women, children and babies. How did you implement the...
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
Balloon kyphoplasty for vertebral compression fractures (IPG166)
Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Gastro-oesophageal reflux in children and young people (QS112)
This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.
View quality statements for QS112Show all sections
Sections for QS112
- Quality statements
- Quality statement 1: Information about gastro-oesophageal reflux (GOR) in infants
- Quality statement 2: Breast-fed infants – feeding assessment
- Quality statement 3: Formula-fed infants – stepped-care approach
- Quality statement 4: Alginate therapy
- Quality statement 5: Symptoms that do not need investigation or treatment
- Quality statement 6: Acid-suppressing drugs
- Quality statement 7: Upper gastrointestinal (GI) contrast study
lead on, or be involved in key projects at NICE, which support national health and care priorities. We can offer excellent opportunities
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
ColonFlag for identifying people at risk of colorectal cancer (MIB142)
NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
receive a quality of life (QALY) gain equivalent to around 30 days perfect health with THC:CBD spray added to standard care. The...
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms
Urinary tract infection in under 16s: diagnosis and management (NG224)
This guideline covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management. It does not cover babies, children and young people with urinary catheters in situ, neurogenic bladders, significant pre-existing urinary tract disorders (uropathies), underlying renal disease or immunosuppression, or recurrent UTI in sexually active girls and young women under 16. It also does not cover babies, children and young people in intensive care units.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .
NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
In development [GID-TA10261] Expected publication date: TBC